# Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

> **NCT05451290** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Biliary Tract Carcinoma

## Interventions

- **DRUG:** Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur

## Key facts

- **NCT ID:** NCT05451290
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2026-12-03
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05451290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05451290, "Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05451290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*